Amgen (AMGN) β†’ Stock, financial statements
Advertising

Amgen

284.32 USD -2.88 (-1.41%)
Mar 28 πŸ‡ΊπŸ‡Έ NASDAQ AMGN
Dividends News
Favorites
  • AMGN Ticker
  • πŸ‡ΊπŸ‡Έ NASDAQ Exchange
  • 21,500 Employees
42 rated
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon

Financial statements β€” Amgen

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
20 ← 16 2020 2019 2018 2017 2016
Total Revenue
25B 23B 24B 23B 23B
Cost Of Revenue
6.2B 4.4B 4.1B 4.1B 4.2B
Gross Profit
19B 19B 20B 19B 19B
Research and Development
4.2B 4.1B 3.7B 3.6B 3.8B
Selling General and Admin
5.7B 5.2B 5.3B 4.9B 5.1B
Operating Expense
16B 14B 13B 13B 13B
Operating Income
9.1B 9.7B 10B 10B 9.8B
Other Income Expense Net
0 0 0 0 0
EBIT
9.1B 9.7B 10B 10B 9.8B
Interest Income
1.3B 1.3B 1.4B 1.3B 1.3B
Pretax Income
8.1B 9.1B 9.5B 9.6B 9.2B
Income Tax
870M 1.3B 1.2B 7.6B 1.4B
Minority Interest
0 0 0 0 0
Net Income
7.3B 7.8B 8.4B 2B 7.7B
Net Income Basic
7.3B 7.8B 8.4B 2B 7.7B
20 ← 16 2020 2019 2018 2017 2016
Current cash
11B 8.9B 29B 42B 38B
Short term investments
1.9B 1.9B 1.8B 1.7B 2B
Receivables
4.7B 4.1B 3.6B 3.2B 3.2B
Inventory
3.9B 3.6B 2.9B 2.8B 2.7B
Other current assets
1.9B 1.9B 1.8B 1.7B 2B
Current assets
21B 18B 38B 49B 46B
Long term investments
42B 41B 29B 30B 32B
Property plant equipment
4.9B 4.9B 5B 5B 5B
Goodwill
15B 15B 15B 15B 15B
Intangible assets
17B 19B 7.4B 8.6B 10B
Other assets
5.6B 2.2B 1.7B 2B 1.5B
Total assets
63B 60B 66B 80B 78B
Accounts payable
1.4B 1.4B 1.2B 1.4B 920M
Current long term debt
91M 3B 4.4B 1.2B 4.4B
Other current liabilities
10B 8.5B 7.9B 6.5B 5.9B
Total current liabilities
12B 13B 13B 9B 11B
Long term debt
33B 27B 30B 34B 30B
Other liabilities
9B 9.6B 10B 10B 3.9B
Minority Interest
0 0 0 0 0
Total Liabilities
54B 50B 54B 55B 48B
Common stock
590M 610M 660M 730M 750M
Retained earning
-21B -21B -18B -5.1B -440M
Treasury stock
0 0 0 0 0
Capital surplus
β€’ β€’ β€’ β€’ β€’
Shareholder equity
9.4B 9.7B 13B 25B 30B
Net tangible assets
-22B -24B -9.6B 1.9B 4.8B
20 ← 16 2020 2019 2018 2017 2016
Net Income
7.3B 7.8B 8.4B 2B 7.7B
Depreciation
3.6B 2.2B 1.9B 2B 2.1B
Changes in receivables
680M 480M 340M 72M 170M
Changes in inventories
310M 640M 110M 89M 310M
Cash change
1.7B -20B -12B 3.6B 6.7B
Cash flow
10B 9.2B 11B 11B 10B
Capital expenditures
-610M -620M -740M -660M -840M
Investments
β€’ β€’ β€’ β€’ β€’
Investing activity other
β€’ β€’ β€’ β€’ β€’
Total investing cash flows
-5.4B -5.7B -14B -4B -8.7B
Dividends paid
β€’ β€’ β€’ β€’ β€’
Net borrowings
20B 19B 2.8B -8.1B -5.5B
Other financing cash flows
β€’ β€’ β€’ β€’ β€’
Cash flow financing
-4.9B -16B -22B -6.6B -2.6B
Exchange rate effect
β€’ β€’ β€’ β€’ β€’

A large multinational biopharmaceutical company. It develops medicines using genetic methods for analyzing the occurrence of disease and biotechnology of disease resistance. This allows us to trace the molecular level of the substance's effect on tissues and understand the mechanism of recovery and functioning of the disease.
Representative offices are located in 100 regions where they are engaged in research and therapy in the following areas: Oncology, cardiovascular and bone diseases, neurology, Nephrology, inflammatory processes of various etiologies. New drugs are used for diseases whose therapy is limited or requires a stronger effect than in classical treatment (late stages of cancer or lack of response of the body). In total, the company has 15 developed and approved medicines for 17 different pathologies.

Since 2019, an experimental cancer drug (AMG 510) being developed by the company has passed phase 1 of clinical trials, and in December received approval from the FDA to begin phase 2 trials.